Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer

Abstract

OBJECTIVES:The aim of this study was to investigate the role of the interleukin-18 +105A/C and interleukin-10 -1082A/G germline polymorphisms in the development and outcome of differentiated thyroid carcinoma associated or not with concurrent thyroiditis.METHODS:We studied 346 patients with differentiated thyroid carcinomas, comprising 292 papillary carcinomas and 54 follicular carcinomas, who were followed up for 12-298 months (mean 76.10±68.23 months) according to a standard protocol. We genotyped 200 patients and 144 control individuals for the interleukin-18 +105A/C polymorphism, and we genotyped 183 patients and 137 controls for the interleukin-10 -1082A/G polymorphism.RESULTS:Interleukin-18 polymorphisms were not associated with chronic lymphocytic thyroiditis or any clinical or pathological feature of tumor aggressiveness. However, there was an association between the presence of interleukin-10 variants and chronic lymphocytic thyroiditis. Chronic lymphocytic thyroiditis was present in 21.74% of differentiated thyroid carcinoma patients, most frequently affecting women previously diagnosed with Hashimoto's thyroiditis who had received a lower 131I cumulative dose and did not present lymph node metastases.CONCLUSIONS:We conclude that the inheritance of a G allele at the interleukin-10 -1082A/G polymorphism may favor a concurrent thyroid autoimmunity in differentiated thyroid carcinoma patients, and this autoimmunity may favor a better prognosis for these patients.

Comments on "Well-Differentiated Thyroid Carcinoma with Concomitant Hashimoto’s Thyroiditis Present with Less Aggressive Clinical Stage and Low Recurrence"

“…In our cohort, 84 out of 266 (31.58%) DTC patients present concomitant HT, suggesting that a genetic population background may be an important factor in concurrent HT manifestation. Indeed, we recently showed that the inheritance of a G allele of interleukin-10-1082A/G polymorphisms may favor a concurrent autoimmunity in DTC patients [4].…”

Histological perspective on the effects of tumor-associated macrophages in the tumor microenvironment surrounding papillary thyroid carcinoma

“…Cunha et al [29] reported that inheritance of the G allele in IL-10-1082 may support lymphocyte migration as an antitumor response and antitumor autoimmunity, yielding better prognosis in differentiated thyroid carcinoma. On the other hand, Yu et al [30] reported that levels of IL-10 were higher in patients with PTC and multinodular disease than in patients with only multinodular disease, and PTC patients may have a special type of regulatory T cells, resulting in a tumor response that facilitates tumor progression.…”

Interleukin-18 Gene Polymorphism and Some Risk Factors in Iraqi Patients With Breast Cancer

“…The alteration from the "C allele to the "A" allele at site −607C/A and at site −137 G/C alternation from the G allele to the C allele in the (promoter area) were prophesied to be the molecular factor linking sites for the cyclic adenosine monophosphate responsive element between protein and H4TF-1 factor, respectively in addition, polymorphisms of the two positions have been correlated with the activity of IL-18 gene promoter transcription, which can impact the IL-18 expression and, may be, of IFN-γ; these changes in alleles, potentially be the essential mechanism of IL-18 involvement in different diseases [23,24]. IL-18 polymorphism has been shown correlated with different diseases such as oral cancer [10], colorectal cancer [11], thyroid cancer [12], bladder cancer [13], lung cancer [14], and nasopharyngeal carcinoma" [15].…”

“…Three types of SNPs of the IL-18 gene in the promoter nucleotides was determined, called −137 G/C (rs187238), −656 G/T or rs1946518, and −607 C/A or rs1946519 [9]. IL-18 gene polymorphisms have shown correlation with different diseases such as oral cancer [10], colorectal cancer [11], thyroid cancer [12], bladder cancer [13], lung cancer [14]. and nasopharyngeal carcinoma [15].…”